Abstract
The COVID-19 pandemic is currently causing several damages to the world, especially in the public health sector. Due to identifiability problems in parameters’ estimation of complex compartmental models, this study considered a simple deterministic susceptible–infectious–recovered (SIR)-type model to characterize and predict the future course of the pandemic in the West African countries. We estimated some specific characteristics of the disease’s dynamics such as its initial conditions, reproduction numbers, true peak and peak of the reported cases, with their corresponding times, final epidemic size and time-varying attack ratio. Our findings revealed a relatively low proportion of susceptible individuals in the region and in the different countries (1.2% across West Africa). The detection rate of the disease was also relatively low (0.9% for West Africa as a whole) and < 2% for most countries, except for Gambia (12.5 %), Cape-Verde (9.5%), Mauritania (5.9%) and Ghana (4.4%). The reproduction number varied between 1.15 (Burkina-Faso) and 4.45 (Niger), and the peak time of the pandemic was between June and July for most countries. Generally, the peak time of the reported cases came a week (7-8 days) after the true peak time. The model predicted 222,100 actual active cases in the region at the peak time, while the final epidemic size accounted for 0.6% of the West African population (2,526,700 individuals). The results obtained showed that COVID-19 has not severely affected West Africa as noticed in other regions of the world. However, current control measures and standard operating procedures should be maintained over time to accelerate a decline in the observed trends of the pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Not applicable
Funding Statement
The autors secured no funds for this research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Section "Discussion" has been improved The entire manuscript has been edited by a native english speaker.
Data Availability
I declare that all data referred in the manuscript are available.
